CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating Activities
Net loss	$ (208,724)	$ (133,187)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	11,384	1,102
Stock-based compensation	91,745	26,719
Accretion of unamortized debt discount and amortization of debt issuance costs	2,016	19
Amortization of premium (accretion of discount) for marketable securities	2,781	0
Deferred income taxes	(479)	0
Change in fair value of common stock warrant liabilities	(5,485)	31,703
Changes in operating assets and liabilities:
Accounts receivable, net	2,867	0
Prepaid expenses and other assets	(5,076)	(4,417)
Operating lease right-of-use assets	1,197	(13,196)
Accounts payable	(17,223)	(2,701)
Operating lease liabilities	(1,087)	14,172
Other accruals and liabilities	(18,930)	14,796
Net cash used in operating activities	(145,014)	(64,990)
Investing Activities
Purchases of property and equipment, including internal-use software	(346)	(1,508)
Investment in non-marketable equity securities	0	(2,000)
Purchases of marketable securities	(327,504)	0
Proceeds from maturities of marketable securities	325,078	0
Proceeds from sales of marketable securities	79,084	0
Net cash provided by (used in) investing activities	76,312	(3,508)
Financing Activities
Principal payments on finance leases obligations	(1,495)	0
Payments for debt issuance costs	(1,998)	0
Proceeds from issuance of common stock in follow-on offering, net of underwriting commissions, and offering costs	0	402,139
Payments made towards deferred offering costs	0	(13,221)
Net proceeds from exercise of stock options and issuance of common stock	852	109
Proceeds from exercise of common stock warrants, net of redemptions	0	109,521
Net cash provided by (used in) financing activities	(2,641)	498,548
Net change in cash, cash equivalents and restricted cash	(71,343)	430,050
Cash, cash equivalents and restricted cash – beginning of year	244,252	265,648
Cash, cash equivalents and restricted cash – end of period	172,909	695,698
Cash paid during the period for:
Interest	15,097	30
Noncash investing and financing activities:
Deferred offering costs and issuance costs in accounts payable and accrued liabilities	(7)	725
Warrant exercise receivable	0	1,185
Warrant liability reclassified to additional paid-in capital	$ 0	$ 71,640